
Smith & Nephew plc
Smith & Nephew plc is a United Kingdom-based company in the Healthcare sector with a market capitalisation of $12.1B. Its FinScore is 66/100; its highest-scoring layer is Quality (72) and its lowest is Growth (48). The shares trade at 18.8x trailing earnings and are down 11% year to date.
Share price performance
About Smith & Nephew plc
www.smith-nephew.comSmith & Nephew plc, along with its subsidiaries, operates globally as a developer, manufacturer, marketer, and seller of medical technology. Its orthopaedic division offers knee implants for replacement procedures and hip implants for joint reconstruction. This segment also provides trauma and extremities products, including internal and external fixation devices crucial for stabilizing severe fractures and correcting deformities. In the sports medicine field, the company furnishes surgeons with comprehensive joint repair solutions. These encompass specialized instruments, advanced technologies, and implants necessary for minimally invasive joint surgeries, addressing soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. Additionally, its arthroscopic enabling technologies support surgical visualization and intervention inside joints, comprising fluid management equipment, high-definition cameras, digital image capture systems, scopes, light sources, and monitors. It also supplies radiofrequency, electromechanical, and mechanical tissue resection devices, along with hand instruments for removing damaged tissue, and provides ear, nose, and throat (ENT) solutions. Furthermore, Smith & Nephew delivers sophisticated advanced wound management solutions. This category features products for the treatment and prevention of acute and chronic wounds, including leg, diabetic, and pressure ulcers, burns, and post-operative wounds. Its offerings extend to advanced wound bioactives, incorporating biologics and other active technologies for debridement, dermal repair, and regeneration, as well as regenerative medicine products like skin, bone graft, and articular cartilage substitutes. The advanced wound devices portfolio includes traditional and single-use negative pressure wound therapy systems, alongside hydrosurgery devices. Primarily serving healthcare providers, Smith & Nephew plc was founded in 1856 and maintains its corporate headquarters in Watford, United Kingdom.
- Sector
- Healthcare
- Industry
- Medical - Devices
- HQ
- United Kingdom
- Fiscal year-end
- December
- Trading currency
- GBP
- Reporting currency
- USD
- Fundamentals updated
- 75 days ago
- Market cap
- $12.1B
- Shares outstanding
- 837.0M
- P/E (TTM)
- 18.8x
- Dividend yield (TTM)
- 2.68%
- Beta (issuer)
- 0.69
- Revenue (latest FY)
- $6.3B
Revenue breakdown
- Orthopaedics, Sports Medicine and Ear Nose and Throat70.9%$4.4B
- Advanced Wound Management29.1%$1.8B
FinScore
As of 2026-10-19Snapshot
Ownership
As of 2026-03-31Sign up or log in to see Analysis
Analysis for Smith & Nephew plc is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Financials
Financials for Smith & Nephew plc is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Estimates
Estimates for Smith & Nephew plc is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Peers
Peers for Smith & Nephew plc is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Valuation
Valuation for Smith & Nephew plc is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see News
News for Smith & Nephew plc is available to Finryse members. The Overview stays open to everyone; creating an account is free.